Icahn To File Lawsuit To Stop Biogen Idec (BIIB) Vote
More News related to BIIB
- InvestorSoup.com Issues Technical Trading Outlook for ARCA biopharma Inc.
- Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
- Biogen Idec to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
More News related to Trader Talk
- Bank of America (BAC) $18.8B Convertible Preferred Offering Coming Monday
- Bank of America (BAC) Paying Back All $45 Billion in TARP
- Bank of America (BAC) will raise capital in order to pay back $45B in TARP
- Apple (AAPL) seeing a repeat of yesterday. Selling off into the close.
- Despite Novartis Denial, UBS Makes A Strong Case That They Should Buy Alcon (ACL)
According to reports from CNBC, an Icahn associate is going to Delaware court to stop the shareholder vote at Biogen Idec Inc. (Nasdaq: BIIB). Biogen Idec has taken a recess until 2PM on the vote, which Icahn views as an attempt to change the vote.
An Icahn associate said they believe that if the vote was stopped now and counted they would have two associates nominated to the board.
Shares of BIIB are up 2.9%
Related Categories
Insiders' BlogTrader Talk
Stocks Mentioned
-0.10Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
